Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Desvenlafaxine extended release.

× No keyword cloud information.

15 in total

1. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.

Authors: Albena Patroneva; Sandra M Connolly; Penny Fatato; Ron Pedersen; Qin Jiang; Jeffrey Paul; Christine Guico-Pabia; Jennifer A Isler; Michael E Burczynski; Alice I Nichols
Journal: Drug Metab Dispos Date: 2008-09-22 Impact factor: 3.922

2. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions.

Authors: Deborah S Hasin; Renee D Goodwin; Frederick S Stinson; Bridget F Grant
Journal: Arch Gen Psychiatry Date: 2005-10

3. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.

Authors: Darlene C Deecher; Chad E Beyer; Grace Johnston; Jenifer Bray; S Shah; M Abou-Gharbia; Terrance H Andree
Journal: J Pharmacol Exp Ther Date: 2006-05-04 Impact factor: 4.030

4. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Authors: Patrice Boyer; Stuart Montgomery; Ulla Lepola; Jean-Michel Germain; Claudine Brisard; Rita Ganguly; Sudharshan K Padmanabhan; Karen A Tourian
Journal: Int Clin Psychopharmacol Date: 2008-09 Impact factor: 1.659

5. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Authors: Michael R Liebowitz; Amy L Manley; Sudharshan K Padmanabhan; Rita Ganguly; Raj Tummala; Karen A Tourian
Journal: Curr Med Res Opin Date: 2008-05-27 Impact factor: 2.580

6. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.

Authors: J F Rosenbaum; M Fava; S L Hoog; R C Ascroft; W B Krebs
Journal: Biol Psychiatry Date: 1998-07-15 Impact factor: 13.382

7. Global burden of depressive disorders in the year 2000.

Authors: T B Ustün; J L Ayuso-Mateos; S Chatterji; C Mathers; C J L Murray
Journal: Br J Psychiatry Date: 2004-05 Impact factor: 9.319

Review 8. Safety and tolerability of antidepressants: weighing the impact on treatment decisions.

Authors: Alan F Schatzberg
Journal: J Clin Psychiatry Date: 2007 Impact factor: 4.384

9. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

Authors: Nicholas A DeMartinis; Paul P Yeung; Richard Entsuah; Amy L Manley
Journal: J Clin Psychiatry Date: 2007-05 Impact factor: 4.384

10. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

Authors: Michael R Liebowitz; Paul P Yeung; Richard Entsuah
Journal: J Clin Psychiatry Date: 2007-11 Impact factor: 4.384

2 in total

Review 1. Clinically significant drug interactions with newer antidepressants.

Authors: Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal: CNS Drugs Date: 2012-01-01 Impact factor: 5.749

Review 2. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.

Authors: Christian Dolder; Michael Nelson; Andrea Stump
Journal: Drugs Aging Date: 2010-08-01 Impact factor: 3.923

2 in total